###### Strengths and limitations of this study

-   This is the first nationwide retrospective observational study of the performance of percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) covering all geographic regions of mainland China.

-   The assessment was based on real-world registry data with sequential enrolment from calendar years 2011--2014.

-   PCI outcomes were based on in-hospital data and no follow-up were done to evaluate the long-term improvement of patients with ACS undergoing PCI.

-   Although all PCI-capable military hospitals participated in this programme, patient outcomes might be differentially affected by interventionist in hospitals with various volumes of PCI procedures each year, thus may confound the overall results.

Introduction {#s1}
============

Due to an ageing population and increasing prevalence of cardiovascular risk factors, China is facing an epidemic of acute coronary syndrome (ACS). In China, military hospitals play an indispensible role in providing healthcare service largely to civilian patients in peacetime,[@R1] yet their performance of care were underinvestigated. The drastic increase of acute coronary syndrome (ACS) in China has also catalysed the growth of percutaneous coronary intervention (PCI) in quantity.[@R6] However, whether the rapid growth of PCI volume has translated into good quality of care for these patients with ACS treated in military hospitals remains unclear. The adoption of emerging technologies varies substantially across different areas of China. The lack of a nationwide comprehensive assessment of interventional practice hampered the improvement of healthcare provided to these patients. Understand these barriers within the healthcare system of China is imperative to implement change.

The China patient-centered evaluative assessment of cardiac event (PEACE) study was a nationally representative, retrospective study of patients undergoing coronary catheterisation and PCI at 55 urban Chinese non-military hospitals in calendar years 2001, 2006 and 2011.[@R6] This study found that there were notable changes in practice, including use of radial PCI and medicated stents, yet persistent gaps still existed to improve care.[@R6] Military hospitals are independently administered by the Joint Logistic Support Center (the former General Logistics Department) of People's Liberation Army (PLA) in China. To facilitate the management of cardiovascular intervention in military hospitals, the Quality Control Center of Intervention for Cardiovascular Diseases was founded in 2009 by the Bureau of Healthcare of the General Logistics Department.[@R7] Quality Improvement Initialtives were launched thereafter to standardise the care of acute myocardial infarction nationwide in military hospitals, including the establishment of Chest Pain Center in qualified cardiac centres.[@R8] To standardise and monitor the quality of care for patients undergoing PCI procedures, we conducted the National Registry of Cardiovascular Intervention in Military Hospitals (NRCIMH) study.[@R9] During calendar years 2011--2014, 117 PCI-capable military hospitals in all seven geographical regions of China and 144 659 patients with ACS undergoing PCI procedures were included in this study. Patient characteristics, quality of procedural performance, PCI outcomes, and in-hospital adverse events and their temporal changes were analysed over time.

Methods {#s2}
=======

Study design {#s2a}
------------

This study was a cross-sectional study using a registered dataset. The original data for this study were extracted from the NRCIMH (web access via <http://www.xxgjr.com>). This database collected social-demographic, medical and interventional data of patients who had cardiovascular disease and underwent cardiac interventions since October 2010 in all military hospitals nationwide that are qualified to perform cardiac catheterization and PCI.[@R9] Patient demographics, clinical characteristics and treatment patterns during hospitalisation were collected by physicians who were in charge of the patient, and coronary catheterisation or PCI-related information were collected by the responsible operator or technical assistant. Patient data were censored and uploaded into the database by designated medical personnel in each individual hospital. The majority of patients had coronary artery disease and underwent PCI. All participating hospitals accepted the ethics committee approval.

Study population {#s2b}
----------------

Patients with ACS (with definite discharge diagnosis of either ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina) undergoing interventional procedures in all 117 military hospitals (online [table S1](#SP1){ref-type="supplementary-material"}) from 1 January 2011 to 31 December 2014 were included in this study. Diagnoses were made according to the China National Guidelines for ACS,[@R12] which are consistent with guidelines in the USA.[@R14] Due to the large-volume information inputed into this registry, patients with missing data were excluded in specific categorical analyses, including age, gender, region of hospital, access artery, contrast type, lesion vessel and target vessel. For measured categories like artery stenosis and lesion category, their sum exceed the total number of patients enrolled in each study year is because each patient usually had more than one stenosed/lesioned vessel. For the sake of clarity, the sum for each measured variable category was listed in the column of each category unless otherwise specified. Data integrity for each measure category was not less than 91.8% in this study.
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Variables and definitions {#s2c}
-------------------------

We collected data from a unified registry form abstracted from the original database systems, including baseline characteristics (diagnosis, patient category, age, gender, ethnicity, region of admission hospital, medical history), perioperative characteristics (primary PCI composition, access artery, contrast type, antiplatelet and anticoagulation medications, assisted devices), PCI outcomes (stenosis pre-PCI, lesion category, lesion vessel, target vessel) and adverse outcomes including complication and death both during PCI and post-PCI. Medical histories including histories of myocardial infarction, cerebrovascular disease, peripheral vascular disease, cardiac valve surgery, coronary artery bypass graft (CABG) and PCI were collected by physicians in charge of that patient (mainly via patient's own statement and further verified, if any, by documentation in previous admission notes, discharge diagnoses or corroborating laboratory test results) and were uploaded into the registry database. For the convenience of calculation, anomalous artery, intermediate artery and vessel graft lesion as well as interventions done in these vessels were all merged into the individual categories. In addition, due to a systematic revision of the registry form since 2013, partial data were analysed and summarised in the supplement, including location and Killip classification of myocardial infarction history, assisted device used during 2011--2013, information regarding medical coverage, thrombolysis of STEMI patient, PCI outcomes and stent manufacturer during 2013--2014.

Patients with corrected TIMI frame count values exceeding the thresholds by \>2 SD for the particular vessel were recognised as having coronary slow flow.[@R16] Major bleeding was defined as any intracranial bleeding, absolute haemoglobin decrease of at least 50 g/L, bleeding resulting in hypovolemic shock or fatal bleeding (bleeding that resulted directly in death within 7 days). Acute/subacute stent thrombosis was defined according to the Academic Research Consortium criteria.[@R17] Postoperative myocardial infarction was diagnosed in accordance with the universal definition of type 4 myocardial infarction.[@R18] The cause of death was adjudicated as cardiogenic death, PCI-related death or uncertain.

Statistical analysis {#s2d}
--------------------

We used percentages to describe categorical variables and median with IQRs to describe continuous variables unless otherwise specified. χ^2^ trend tests were used to examine trends across different study years for categorical variables. For the comparison of data between 2013 and 2014, χ^2^ tests were used for categorical variables and Mann-Whitney tests for continuous variables with non-normal distribution. We constructed three indicator variables representing years 2012, 2013 and 2014, leaving 2011 as the reference. We did logistic regressions including these indicators for time as key explanatory variables, while adjusting for patients' ACS types (unstable angina, NSTEMI, STEMI), demographics (age and sex), comorbidities (hypertension, hyperlipidemia, diabetes mellitus, chronic obstructive pulmonary disease, current smoking, heart failure, renal failure, under dialysis, prior cerebrovascular disease, prior peripheral vascular disase, prior PCI, prior cardiac valve surgery, prior CABG). The dependent variable was in-hospital death. We also tested the linear trend over time in the models. We report ORs and 95% CIs from the multilevel logistic regression related to the year indicators. All comparisons were two-sided, with statistical significance defined as p\<0.05. Statistical analyses were performed using GraphPad Prism V.6.01 and SAS software V.9.3.

Patient and public involvement {#s2e}
------------------------------

Patients and public were not involved in this study.

Results {#s3}
=======

A total of 144 659 patients with ACS undergoing PCI in 117 military hospitals were recruited into this study from 2011 to 2014, located in all seven geographic regions of mainland China, including North China (n=25), Northwest (n=14), Northeast (n=10), East China (n=29), Southwest (n=14), Central China (n=12) and South China (n=13). Of these, 82 hospitals provided 140 374 cases (97.0%) across all the study years (online [table S1](#SP1){ref-type="supplementary-material"}). In brief, only 20 (17.1%) hospitals performed more than 400 PCIs on ACS patients annually ([figure 1A](#F1){ref-type="fig"}), and these hospitals performed 71.9% PCIs (104 026 cases) during 2011--2014 ([figure 1B](#F1){ref-type="fig"}). Geographically, although the total number of hospitals in Northern China (North China, Northwest, Northeast regions) was less than that in Southern China (South China, East China, Central China and Southwest regions), there were more military hospitals in Northern China performed PCI procedures\>400 cases per year than those in Southern China ([figure 1C](#F1){ref-type="fig"}), and northern military hospitals performed the majority of PCIs during the study years (66.5%) ([figure 1D](#F1){ref-type="fig"}).

![Overall and regional distributions of percutaneous coronary intervention (PCI)-capable military hospitals and PCI procedures performed. Military hospitals were divided by their annual PCI volume with a threshold of 400 cases per year (A), as well as further by geographical regions (C); the overall PCI procedures performed during 2011--2014 were also grouped by annual PCI volumes of hospitals (B) and by regions (D). Northern China include North China, Northwest China and Northeast China, Southern China include South China, East China, Central China and Southwest China.](bmjopen-2018-023133f01){#F1}

Generally, the number of patients with ACS undergoing PCI has increased by 27.8%, while the proportions of most comorbidities of these patients had concordant decrease over time. Hospitals in northern China (North China, Northwest and Northeast) performed the majority of PCIs, with most patients being civilian and with Han ethnicity. There were significant increases in the proportions of patients diagnosed as unstable angina pectoris, of civilian identity, male gender, treated in hospitals in Northeast, East and South China, and significant decreases in the proportions of patients diagnosed as STEMI, treated in hospitals in North China, Northwest and Central China ([table 1](#T1){ref-type="table"}). During 2013--2014, only half of these patients were covered by urban resident medical service (53.4%--53.6%) (online [table S2](#SP1){ref-type="supplementary-material"}).

###### 

Baseline characteristics of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) during 2011--2014

  --------------------------------------------------------------------------------------------------
                       2011     2012   2013     2014   P values\                          
                                                       for trend                          
  -------------------- -------- ------ -------- ------ ----------- ------ -------- ------ ----------
  ACS                  30 800          34 974          39 524             39 361          

   UAP                 22 038   71.6   24 847   71.0   28 727      72.7   28 508   72.4   \<0.0001

   STEMI               6514     21.1   7302     20.9   7889        20.0   7856     20.0   \<0.0001

   NSTEMI              2248     7.3    2825     8.1    2908        7.4    2997     7.6    0.87

  Age, years           30 651          34 872          39 466             39 351          

   18--24              12       0.0    8        0.0    16          0.0    15       0.0    0.70

   25--34              177      0.6    223      0.6    246         0.6    243      0.6    0.62

   35--44              1597     5.2    1930     5.5    2149        5.4    2187     5.6    0.09

   45--54              5849     19.1   6663     19.1   7283        18.5   7507     19.1   0.52

   55--64              10 291   33.6   11 990   34.4   13 888      35.2   13 381   34.0   0.11

   65--74              8615     28.1   9510     27.3   10 650      27.0   10 832   27.5   0.09

   75--84              3850     12.6   4227     12.1   4884        12.4   4800     12.2   0.33

   \>84                260      0.8    321      0.9    350         0.9    386      1.0    0.11

  Gender               30 155          34 191          39 189             39 336          

   Male                22 017   73.0   25 423   74.4   29 104      74.3   29 193   74.2   \<0.01

   Female              8138     27.0   8768     25.6   10 085      25.7   10 143   25.8   

  Ethnicity            30 800          34 974          39 524             39 361          

   Han                 30 589   99.3   34 691   99.2   38 974      98.6   38 620   98.1   \<0.0001

   Others              211      0.7    283      0.8    550         1.4    741      1.9    

  Region of hospital   30 783          34 970          39 524             39 361          

   North China         9156     29.7   9631     27.5   9914        25.1   11 086   28.2   \<0.0001

   Northwest           7632     24.8   7939     22.7   9728        24.6   7821     19.9   \<0.0001

   Northeast           3924     12.7   5347     15.3   6691        16.9   7284     18.5   \<0.0001

   East China          3742     12.2   4630     13.2   5053        12.8   5241     13.3   \<0.001

   Southwest           3515     11.4   4346     12.4   4877        12.3   4549     11.6   0.96

   Central China       1977     6.4    1928     5.5    1910        4.8    1944     4.9    \<0.0001

   South China         837      2.7    1149     3.3    1351        3.4    1436     3.6    \<0.0001

  Comorbidities        30 800          34 974          39 524             39 361          

   Hypertension        17 600   57.1   19 942   57.0   21 260      53.8   21 701   55.1   \<0.0001

   Hyperlipidaemia     6844     22.2   7774     22.2   7420        18.8   7330     18.6   \<0.0001

   Diabetes mellitus   6829     22.2   7817     22.4   8394        21.2   8819     22.4   0.75

   COPD                541      1.8    448      1.3    478         1.2    447      1.1    \<0.0001

   Current smoking     9093     29.5   10 838   31.0   11 467      29.0   10 568   26.8   \<0.0001

   Heart failure\*     1378     4.5    1373     3.9    1331        3.4    1122     2.9    \<0.0001

   Renal failure\*     277      0.9    297      0.8    259         0.7    276      0.7    \<0.001

    Under dialysis\*   34       0.1    52       0.1    45          0.1    45       0.1    0.71

   Prior MI            7560     24.5   7828     22.4   7928        20.1   5648     14.3   \<0.0001

   Prior CVD           2014     6.5    1912     5.5    1990        5.0    2018     5.1    \<0.0001

   Prior PVD           457      1.5    430      1.2    489         1.2    515      1.3    0.09

   Prior PCI           5702     18.5   6125     17.5   6467        16.4   5973     15.2   \<0.0001

   Prior CVS           1077     3.5    1192     3.4    563         1.4    14       0.0    \<0.0001

   Prior CABG          936      3.0    952      2.7    580         1.5    204      0.5    \<0.0001

   Familial CAD        805      2.6    867      2.5    681         1.7    615      1.6    \<0.0001
  --------------------------------------------------------------------------------------------------

\*Assessed and recorded at admission.

CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; CVS, cardiac valve surgery; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PVD, peripheral vascular disease; STEMI, ST elevation myocardial infarction; UAP, unstable angina pectoris.

The proportion of primary PCI dropped significantly in patients with ACS in all categories. In STEMI patients, the fraction of primary PCI in all PCI performed did not change dramatically (44.0%--47.9%, [table 2](#T2){ref-type="table"}). There is remarkable increase in the proportion of anterior myocardial infarction and significant decrease in the proportion of cardiac function defined as Killip III/IV (online [table S3](#SP1){ref-type="supplementary-material"}). There was more time delay on first medical contact to balloon dilation in 2014 than in 2013 (median 50 vs 40, p\<0.01) (online [table S4](#SP1){ref-type="supplementary-material"}). PCI procedures done through the radial artery had increased markedly from 72% in 2011 to 90.4% in 2014. The use of clopidogrel and GP IIb/IIIa inhibitor dropped significantly. Proportions of novel drugs like ticagrelor and bivalirudin, and of assisted devices such as intra-aortic balloon pump (IABP), intravascular ultrasound (IVUS), optical coherence tomography (OCT) and fractional flow reserve (FFR) measurement, were low in all time periods ([table 2](#T2){ref-type="table"}, online [table S5](#SP1){ref-type="supplementary-material"}). In addition, from 2013 to 2014, thrombolysis in patients with STEMI was not altered in terms of performance rate, thrombolytics and time delay from angina to thrombolysis increased remarkably and the success rate dropped significantly as well (online [table S6](#SP1){ref-type="supplementary-material"}).

###### 

Perioperative characteristics of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) during 2011--2014

                           2011        2012   2013        2014   P valuesfor trend                             
  ------------------------ ----------- ------ ----------- ------ ------------------- ------ ----------- ------ ----------
  pPCI                     30 800             34 974             39 524                     39 361             
   Yes                     3689        12.0   4359        12.5   4263                10.8   4211        10.7   \<0.0001
    On STEMI               2866        9.3    3499        10.0   3505                8.9    3544        9.0    \<0.01
     pPCI/PCI              2866/6514   44.0   3499/7302   47.9   3505/7889           44.4   3544/7856   45.1   0.78
    On NSTEMI              334         1.1    372         1.1    349                 0.9    365         0.9    \<0.01
    On UAP                 489         1.6    488         1.4    409                 1.0    302         0.8    \<0.0001
   No                      27 111      88.0   30 615      87.5   35 261              89.2   35 150      89.3   
  Access artery            30 800             34 800             39 524                     39 361             
   Radial                  22 171      72.0   28 266      81.2   34 520              87.3   35 582      90.4   \<0.0001
   Femoral                 8453        27.4   6527        18.7   4803                12.2   3545        9.0    \<0.0001
   Brachial                165         0.5    170         0.5    187                 0.5    209         0.5    0.94
   Others                  11          0.0    11          0.0    14                  0.0    25          0.1    0.06
  Contrast type            30 080             34 154             38 585                     39 361             
   Non-ionic               30 027      99.8   34 119      99.9   38 493              99.8   39 198      99.6   \<0.0001
   Iso-osmolar             10 055      33.4   12 988      38.0   16 540              42.9   20 034      50.9   \<0.0001
   Low-osmolar             19 972      66.4   21 131      61.9   21 953              56.9   19 164      48.7   \<0.0001
  Ionic                    53          0.2    35          0.1    92                  0.2    163         0.4    \<0.0001
   Antiplatelet            30 800             34 974             39 524                     39 361             
   Aspirin                 29 459      95.6   34 189      97.8   38 267              96.8   38 547      97.9   \<0.0001
   Clopidogrel             29 486      95.7   34 231      97.9   37 165              94.0   36 122      91.8   \<0.0001
   Ticagrelor              30          0.1    13          0.0    222                 0.6    1299        3.3    \<0.0001
   Ticlopidine             54          0.2    50          0.1    520                 1.3    1202        3.1    \<0.0001
   Cilostazol              22          0.1    17          0.0    23                  0.1    15          0.0    0.11
   GP IIb/IIIa inhibitor   4670        15.2   6232        17.8   6135                15.5   5099        13.0   \<0.0001
  Anticoagulation          30 800             34 974             39 524                     39 361             
   UFH                     18 788      61.0   21 343      61.0   22 885              57.9   24 547      62.4   0.19
   LMWH                    9248        30.0   10 398      29.7   12 622              31.9   12 012      30.5   \<0.01
   Fondaparinux            373         1.2    939         2.7    886                 2.2    0           0.0    \<0.0001
   Bivalirudin             0           0.0    0           0.0    93                  0.2    395         1.0    \<0.0001
  IABP                     30 800             34 974             39 524                     39 361             
   Yes                     450         1.5    579         1.7    584                 1.5    432         1.1    \<0.0001
   No                      30 350      98.5   34 395      98.3   38 940              98.5   38 929      98.9   
  IVUS                     30 800             34 974             39 524                     39 361             
   Yes                     439         1.4    399         1.1    383                 1.0    439         1.1    \<0.0001
   No                      30 361      98.6   34 575      98.9   39 141              99.0   38 922      98.9   

GP IIb/IIIa, glycoprotein IIb/IIIa; IABP, intra-aortic balloon pump; IVUS, intravascular ultrasound; LMWH, low molecular weight heparin; NSTEMI, non-ST elevation myocardial infarction; pPCI, primary percutaneous coronary intervention; STEMI, ST elevation myocardial infarction; UAP, unstable angina pectoris; UFH, unfractionated heparin.

Under catheterisation, artery stenosis \>75% increased significantly in proportions during the study years. Long lesion constitutes approximately one-third of the overall lesions, there were increased trends in the proportion of general lesion, total occluded lesion and thrombus lesion, and decreased trends in long lesion, calcified lesion and bifurcation lesion. The proportion of triple-vessel lesion significantly decreased, while that of solitary vessel lesion increased dramatically. Under PCI, target vessels were primarily solitary with increased trends in proportions of all arteries, followed by double vessels with decreased proportions. Target vessels involving LM consist 3.4% to 4.2% of all PCI procedures. PCI procedures targeting triple vessels had also decreased both in amount and in proportion ([table 3](#T3){ref-type="table"}). From 2013 to 2014, the mean implanted stent per patient decreased from 1.5 to 1.4 (p\<0.01) (online [table S7](#SP1){ref-type="supplementary-material"}), the majorities implanted stents were made by domestic companies with a decreased proportion over time (online [table S8](#SP1){ref-type="supplementary-material"}).

###### 

percutaneous coronary intervention (PCI) characteristics of patients with acute coronary syndrome (ACS) during 2011--2014

                           2011     2012   2013     2014   P values for trend                          
  ------------------------ -------- ------ -------- ------ -------------------- ------ -------- ------ ----------
  Artery stenosis (%)      39 090          42 260          46 915                      46 938          
   75--99                  27 879   71.3   31 048   73.5   34 976               74.6   35 971   76.6   \<0.0001
   100                     7228     18.5   8642     20.4   9704                 20.7   9385     20.0   \<0.0001
   50--75                  3557     9.1    2326     5.5    2003                 4.3    1540     3.3    \<0.0001
   \<50                    426      1.1    244      0.6    232                  0.5    42       0.1    \<0.0001
  Lesion category          38 606          41 713          46 292                      46 073          
   Long lesion\*           13 571   35.2   14 939   35.8   16 375               35.4   15 736   34.2   \<0.001
   General lesion          12 686   32.9   13 036   31.3   14 874               32.1   15 878   34.5   \<0.0001
   Total occluded lesion   4597     11.9   5532     13.3   6058                 13.1   5930     12.9   \<0.001
   Calcified lesion        3184     8.2    3006     7.2    3473                 7.5    2781     6.0    \<0.0001
   Bifurcation lesion      2545     6.6    2463     5.9    2479                 5.4    2891     6.3    \<0.01
   Thrombus lesion         1782     4.6    2469     5.9    2711                 5.9    2549     5.5    \<0.0001
   Small vessel†           217      0.6    246      0.6    277                  0.6    272      0.6    0.59
   Bypass graft lesion     24       0.1    22       0.1    45                   0.1    36       0.1    0.12
  Lesion vessel‡           30 457          34 800          39 427                      39 295          
   Triple                  12 298   40.4   12 803   36.8   13 253               33.6   12 301   31.3   \<0.0001
   Solitary                8580     28.2   11 567   33.2   14 395               36.5   14 912   37.9   \<0.0001
    LAD                    5397     17.7   7090     20.4   8544                 21.7   8599     21.9   \<0.0001
    RCA                    2147     7.0    3111     8.9    3866                 9.8    4222     10.7   \<0.0001
    LCX                    1036     3.4    1366     3.9    1985                 5.0    2038     5.2    \<0.0001
   Double                  7308     24.0   8104     23.3   9180                 23.3   9374     23.9   0.84
    LAD+RCA                3694     12.1   3936     11.3   4270                 10.8   4285     10.9   \<0.0001
    LAD+LCX                2558     8.4    2968     8.5    3475                 8.8    3554     9.0    \<0.001
    LCX+RCA                1056     3.5    1200     3.4    1435                 3.6    1535     3.9    \<0.001
   Triple+LM               1540     5.1    1481     4.3    1638                 4.2    1644     4.2    0.0001
   Double+LM               489      1.6    502      1.4    574                  1.5    593      1.5    0.41
    LAD+LCX + LM           230      0.8    247      0.7    339                  0.9    315      0.8    0.16
    LAD+RCA + LM           195      0.6    212      0.6    198                  0.5    215      0.5    \<0.05
    LCX+RCA + LM           64       0.2    43       0.1    37                   0.1    63       0.2    0.09
   Solitary+LM             178      0.6    253      0.7    300                  0.8    367      0.9    \<0.0001
    LAD+LM                 139      0.5    197      0.6    220                  0.6    281      0.7    \<0.0001
    RCA+LM                 26       0.1    37       0.1    51                   0.1    49       0.1    0.09
    LCX+LM                 13       0.0    19       0.1    29                   0.1    37       0.1    \<0.01
   LM                      64       0.2    90       0.3    107                  0.3    128      0.3    \<0.01
  Target vessel‡           28 278          32 836          38 176                      39 224          
   Solitary                20 801   73.6   25 513   77.7   30 592               80.1   31 456   80.2   \<0.0001
    LAD                    10 735   38.0   13 277   40.4   15 749               41.3   15 960   40.7   \<0.0001
    LCX                    3017     10.7   3563     10.9   4665                 12.2   4867     12.4   \<0.0001
    RCA                    7049     24.9   8673     26.4   10 178               26.7   10 629   27.1   \<0.0001
   Double                  5713     20.2   5685     17.3   5906                 15.5   5886     15.0   \<0.0001
    LAD+LCX                2723     9.6    2683     8.2    2865                 7.5    2815     7.2    \<0.0001
    LAD+RCA                1978     7.0    1937     5.9    1904                 5.0    1932     4.9    \<0.0001
    LCX+RCA                1012     3.6    1065     3.2    1137                 3.0    1139     2.9    \<0.0001
   Solitary+LM             566      2.0    603      1.8    690                  1.8    923      2.4    \<0.001
    LAD+LM                 482      1.7    531      1.6    600                  1.6    782      2.0    \<0.01
    LCX+LM                 68       0.2    58       0.2    71                   0.2    123      0.3    \<0.05
    RCA+LM                 16       0.1    14       0.0    19                   0.0    18       0.0    0.68
   Double+LM               483      1.7    455      1.4    462                  1.2    464      1.2    \<0.0001
    LAD+LCX + LM           405      1.4    375      1.1    387                  1.0    382      1.0    \<0.0001
    LAD+RCA + LM           73       0.3    69       0.2    69                   0.2    72       0.2    \<0.05
    LCX+RCA + LM           5        0.0    11       0.0    6                    0.0    10       0.0    0.92
   Triple                  568      2.0    433      1.3    354                  0.9    298      0.8    \<0.0001
   LM                      97       0.3    113      0.3    153                  0.4    173      0.4    \<0.05
   Triple+LM               50       0.2    34       0.1    19                   0.0    24       0.1    \<0.0001

\*Denotes length of lesion \>20 mm.

†Denotes vessel diameter \<2.5 mm.

‡Include anomalous artery, intermediate artery and vessel graft.

LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main artery; RCA, right coronary artery.

In general, more complications were recorded during PCI than post PCI, and the overall complications were significantly decreased both in amount and in proportion, either during PCI or post-PCI. During PCI procedures, slow flow, serious dissection, acute thrombosis, perforation and cardiac tamponade had markedly decreased. As for complications after PCI, acute/subacute stent thrombosis, organ failure, major bleeding/haematoma, contrast reaction and thromboembolism had decreased trends in proportion during the study years. There were also significantly decreased trends of death both in amount and in proportion, during/after PCI, with the majority of death found after PCI procedures due to cardiogenic triggers ([table 4](#T4){ref-type="table"}). After adjustment for patient demographic and clinical characteristics in the multilevel logistic regression, the risk of in-hospital mortality also significantly decreased over time ([figure 2](#F2){ref-type="fig"}).

###### 

In-hospital adverse events of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) during 2011--2014

                              2011   2012   2013   2014   P values trend                      
  --------------------------- ------ ------ ------ ------ ---------------- ------ ----- ----- ----------
  Complication                496    16.1   539    15.4   429              10.9   256   6.5   \<0.0001
  During procedure\*          342    11.1   334    9.5    269              6.8    151   3.8   \<0.0001
   Slow flow                  201    6.5    168    4.8    159              4.0    87    2.2   \<0.0001
   Serious dissection         71     2.3    75     2.1    64               1.6    32    0.8   \<0.0001
   Acute thrombosis           54     1.8    48     1.4    36               0.9    23    0.6   \<0.0001
   Perforation                22     0.7    32     0.9    17               0.4    17    0.4   \<0.05
   Cardiac tamponade          11     0.4    17     0.5    9                0.2    7     0.2   \<0.05
   Acute occlusion            11     0.4    24     0.7    19               0.5    12    0.3   0.38
  Post-procedure              154    5.0    205    5.9    160              4.0    105   2.7   \<0.0001
   Acute/subacute ST          46     1.5    49     1.4    37               0.9    30    0.8   \<0.001
   Organ failure              37     1.2    31     0.9    29               0.7    19    0.5   \<0.001
    Organ support             8      0.3    2      0.0    7                0.2    3     0.0   0.15
   Major bleeding/haematoma   19     0.6    19     0.5    23               0.6    6     0.2   \<0.01
   Organ bleeding             14     0.5    21     0.6    11               0.3    11    0.3   0.06
   Postoperative MI           10     0.3    20     0.6    14               0.4    7     0.2   0.10
   Contrast reaction          7      0.2    10     0.3    3                0.0    2     0.0   \<0.01
   Postoperative infection    5      0.2    6      0.2    8                0.2    3     0.0   0.40
   Thromboembolism            4      0.1    11     0.3    2                0.0    2     0.0   \<0.05
   Emergent surgery           4      0.1    2      0.0    1                0.0    2     0.0   0.18
   Others                     28     0.9    56     1.6    43               1.1    26    0.7   0.06
  Death                       166    5.4    179    5.1    150              3.8    113   2.9   \<0.0001
  During PCI                  41     1.3    30     0.9    22               0.6    16    0.4   \<0.0001
   Cardiogenic                                                                                
   Yes                        34     1.1    25     0.7    16               0.4    16    0.4   \<0.0001
   No                         1      0.0    1      0.0    2                0.0    0     0.0   0.52
   Uncertain                  6      0.2    4      0.1    4                0.1    0     0.0   \<0.05
  PCI related                                                                                 
   Yes                        4      0.1    1      0.0    1                0.0    4     0.1   0.76
   No                         23     0.7    15     0.4    11               0.3    11    0.3   \<0.01
   Uncertain                  14     0.5    14     0.4    10               0.3    1     0.0   \<0.001
  Post-PCI                    125    4.1    149    4.3    128              3.2    97    2.5   \<0.0001
  Cardiogenic                                                                                 
   Yes                        102    3.3    108    3.1    108              2.7    82    2.1   \<0.01
   No                         10     0.3    22     0.6    8                0.2    9     0.2   0.08
  Uncertain                   13     0.4    19     0.5    12               0.3    6     0.2   \<0.05
  PCI related                                                                                 
   Yes                        4      0.1    5      0.1    7                0.2    8     0.2   0.40
   No                         88     2.9    120    3.4    100              2.5    80    2.0   \<0.01
   Uncertain                  33     1.1    24     0.7    21               0.6    9     0.2   \<0.0001

MI, myocardial infarction; ST, stent thrombosis.

![Adjusted in-hospital mortality for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Adjusted OR of 1 shows no difference from year 2011. We included 1 43 063 patients (30 202 in 2011, 34 304 in 2012, 39 206 in 2013 and 39 351 in 2014).](bmjopen-2018-023133f02){#F2}

Discussion {#s4}
==========

To the best of our knowledge, this is the first large, nationwide study of patients with ACS undergoing PCI in Chinese military hospitals. Compared with contemporary developed country such as the USA, the proportion of hospitals capable of performing PCIs \>400 cases was substantially low (17.1% vs 41.5% in USA).[@R19] Accordingly, the application rates of assisted devices were also low, such as IABP (1.1%--1.7%), temporary pacemaker (1.9%--2.4%), IVUS (1.0%--1.4%), OCT (0.1%) and FFR measurement (0.1%--0.5%) as the support is available with experienced interventional cardiologists and skilled support staff in high-volume well-equipped facilities. Out data also suggest great regional disparities of PCI procedures performed on patients with ACS, with patients in the north region of China (North China, Northwest and Northeast) consumed the majority of interventional resources (65.5%--67.2% of all PCI cases for patients with ACS, [table 1](#T1){ref-type="table"}). This also reflects pandemic state of unstable coronary artery disease in these regions.[@R20] In this regard, medical resources shall be prioritised to better serve disparate needs in different regions, especially the north region of China. Furthermore, the healthcare coverage system in contemporary China is also concerning, as during 2013--2014 only 53.4%--53.6% patients with ACS were covered under urban resident medical service with high reimbursement rate, while 20.1%--22.1% patients were covered under new rural cooperative medical service with low reimbursement rate, and 16.3%--17.2% patients were uncovered.[@R23] Given the great economic burdens patients with ACS bear on PCI procedures and medications during hospitalisation and thereafter,[@R26] the current medical coverage patterns shall be optimised to improve the quality of life for these patients as well as their families. Nevertheless, the overall decreased trends in proportions of comorbidities suggest the effectiveness of cardiovascular-related disease control during 2011--2014 in China.

Primary PCI was performed with high prevalence in hospitals of developed countries. For example, in a recent nationwide Belgian STEMI registry during 2009--2013, 89.6% of patients with STEMI underwent primary PCI.[@R29] In the US National Cardiovascular Data Registry (NCDR) 2010--2011 report, the primary PCI consisted 84.8% of all PCI performed for patients with STEMI.[@R30] However, the proportion of primary PCI performed on STEMI patients was still very low in this study, and this proportion did not change significantly over time (44.0% in 2011 to 45.1% in 2014). This could be explained by the low proportion of high-volume PCI-capable hospitals in China as these hospitals are well-equipped with experienced interventional cardiologists and skilled support staff, which are all required for the successful implementation of primary PCI. Nevertheless, median time delay of first medical contract (FMC) to balloon dilation for primary PCIs done with patients with STEMI during 2013--2014 were 50 min, which were far below the guideline-recommended threshold of 90 min.[@R31] This important quality improvement might be catalysed by the awareness of the performance metric for participating hospitals as the study demonstrated that patients treated in hospitals that had been enrolled in the D2B Alliance for \>3 months were significantly more likely to have D2B times of \<90 min than patients treated in non-enrolled hospitals.[@R32] In this regard, the scenario of D2B time in real-world practice might be less satisfying as performance metrics were largely unmonitored. Furthermore, given that time delay of angina onset to FMC was still huge (median 270 min), great efforts are still needed to promote broader initiatives at a systems level to reduce total ischaemic time, which was shown as the principal determinant of outcome.[@R33] These efforts might include patient education, improvements in emergent medical service and emergent department care, establishment of networks of non-PCI-capable and PCI-capable hospitals, and work with policymakers to implement healthcare system reform.[@R35]

The current study depicted several notable changes as compared with the former China PEACE study. In their study, Xin Zheng and colleagues reported dramatic increase of the adoption of radial artery access from 3.5% to 79.0% in the practice of interventional cardiology in China during 2001--2011.[@R6] In this study of patients with ACS, the trend is still rising, with 72.0% PCI procedures accessed via radial artery in 2011 to 90.4% in 2014, compared with 10.9% cases/procedures performed by means of a radial approach in 2011 to 25.2% in 2014 in the USA (NCDR). Also, the China PEACE-Retrospective CathPCI Study group reported that the proportions of patients who received a glycoprotein IIb/IIIa inhibitor and clopidogrel both increased from 2001 to 2011 in non-military hospitals in China.[@R6] Unlike their findings, in our study, the proportions of clopidogrel and glycoprotein IIb/IIIa inhibitor both decreased significantly (95.7% to 91.8% and 15.2% to 13.0%, respectively), it might suggest different patterns of medications between non-military hospitals and military hospitals in the field of interventional cardiology, or just be a result of rapidly evolved medical practice in all hospitals in contemporary China, possibly due to the emergence of novel P2Y12 inhibitor ticagrelor and novel anticoagulant bivalirudin in China. Meanwhile, operators implanted less stents per patient in 2014 than in 2013 (mean 1.4 vs 1.5), which was also remarkably less than those implanted during 2001--2011 in China PEACE study (mean 1.4 in 2001, 1.7 in 2006 and 1.8 in 2011).[@R6] This may be as a result of the enforcement of quality improvement initiatives during 2011--2014 by the Quality Control Center of Intervention for Cardiovascular Diseases.[@R7] Finally, although domestic-made stents consist the majority of stents used during PCI procedures, their proportion dropped significantly (65.1% in 2013 to 61.8% in 2014), which was quite different from the scenario of dramatic increase of domestic stents used in non-military hospitals in China PEACE study during 2001--2011 (1.6% in 2001 to 74.8% in 2011).[@R6]

In a recent meta-analysis of large, high-quality, contemporary randomised studies comparing radial and femoral access in invasively managed patients with ACS, radial access was found to reduce mortality, major adverse cardiovascular events and major bleeding.[@R42] Similarly, with the rising adoption of radial access from 2011 to 2014 in this study, the proportion of major bleeding or haematoma after PCI and in-hospital mortality were both significantly decreased over time. In this regard, transradial access shall be advocated in countries that use it less frequently.

Compared with data reported from the NCDR in the USA during 2010--2011,[@R30] uses of ticagrelor and bivalirudin were extremely low for patients with ACS undergoing PCI during 2011--2014 (\<3.3% and 1.0%, respectively), although their proportions were rising. This might be explained by the delayed introduction of these drugs into Chinese pharmaceutical market, as well as uncovered status under the drug list of Medical Service in China. Given the great superiorities of these novel antiplatelet and anticoagulation drugs,[@R1] coordinated advocacy efforts are needed to work with policymakers to include these drugs into the list for coverage, to improve the quality of care for patients with ACS and the outcomes of PCI procedures. Nevertheless, our data demonstrated great improvement in the quality metrics of PCI procedures during the study years. The proportion of non-obstructive CAD (stenosis \<50%) was 1.1% in 2011. Although the proportion is much higher than that reported in NCDR during 2010--2011 (0.2%), it has dropped substantially to 0.1% in 2014. Out study also revealed dramatic changes in the pattern of the extent of CAD, with the dominance of three-vessel disease in 2011 (40.4%) shifted to the dominance of one-vessel disease in 2014 (37.9%) and no obvious change in two-vessel disease (23.3%--24.0%). This trend was quite different with distributions found in patients undergoing PCI in the USA during 2010--2011 (38.1%, 32.6% and 39.1% for one-vessel, two-vessel and three-vessel disease, respectively).[@R30] In treated lesion vessels, although there were remarkable increase of one-vessel disease and significant decreases of two-vessel and three-vessel diseases in proportions, interventional operators in Chinese military hospitals still treated lower proportion of one-vessel disease and higher proportion of two-vessel disease in 2014 than peers in the USA during 2010--2011 (80.2% vs 86.2% and 15.0% vs 12.8%, respectively).[@R30] Of note, the proportion of treated vessels involving left main artery (3.4%--4.2%) was significantly higher than proportions reported in the USA during 2010--2011 (1.8%)[@R21] as well as in Chinese non-military hospitals during 2001--2011 (0.4%--2.1%) in China PEACE study.[@R6] The facts that considerable amount of grade 0--2 TIMI flow before PCI almost disappeared after PCI suggest high quality of performance of PCI procedures. Especially, compared with data in 2013, higher proportions of grade 0 and 1 TIMI flow before PCI turned to higher proportion of grade 3 TIMI flow after PCI in 2014, suggesting the quality of performance was still improving. The relatively low and decreasing rate of overall complications (1.6% in 2011 to 0.7% in 2014) and death (0.5% in 2011 to 0.3% in 2014) for PCI procedures might be attributable to the decrease of worse cardiac function over time (patients with Killip III--IV grades decreased significantly from 2011 to 2013, online [table S3](#SP1){ref-type="supplementary-material"}). On the other hand, the consistent low rates are also suggestive of good performance of cardiac intervention on these patients.

Some limitations of this study should be noted. First, the partial revision of the registry form in 2013 has made comparisons of some critical measures impossible during 2011--2014 consecutively. However, the purpose of the necessary revision was to reflect contemporary changes in the practice of cardiac intervention during the study years. And we analysed all critical measures provided they were available. Second, due to the gigantic number of nationwide enrolled patients and limit of sufficient funding and other resources, we only compared the in-hospital outcomes for the patients. However, it is possible to follow-up the long-term outcomes for these patients, given that contact information of most patients were collected. Third, in this study comparisons of data with other studies were not matched exactly both temporally and categorically, as to the best of our knowledge, the same large-scale, nationwide registries of acute coronary syndromes during the same study period were not available. Nevertheless, we believe this study has given an updated and comprehensive overview of contemporary practice of interventional cardiology in military hospitals in China.

Conclusion {#s5}
==========

This study outlined the general profiles of cardiac intervention practice in contemporary military hospital in China. Our data revealed the overall interventional resources were still limited in military hospitals, with great disparities of resources and consumptions in different geographical regions across China, and major gaps still exist in optimal medical coverage for patients with ACS. Other than data from non-military hospitals, our findings can serve as an indispensable addition to a comprehensive overview of the practice of cardiac intervention in China.
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